Cargando…

Capecitabine-Associated Terminal Ileitis

Capecitabine is an oral fluoropyrimidine used as adjuvant and palliative chemotherapy in patients with colorectal cancer. Diarrhea is a well-known side effect of capecitabine and 5-fluorouracil agents. We present a case with terminal ileitis as a rare adverse event of capecitabine treatment. Capecit...

Descripción completa

Detalles Bibliográficos
Autores principales: van Hellemond, Irene E.G., Thijs, Annemarie M., Creemers, Geert-Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243901/
https://www.ncbi.nlm.nih.gov/pubmed/30483093
http://dx.doi.org/10.1159/000492781
_version_ 1783372004778311680
author van Hellemond, Irene E.G.
Thijs, Annemarie M.
Creemers, Geert-Jan
author_facet van Hellemond, Irene E.G.
Thijs, Annemarie M.
Creemers, Geert-Jan
author_sort van Hellemond, Irene E.G.
collection PubMed
description Capecitabine is an oral fluoropyrimidine used as adjuvant and palliative chemotherapy in patients with colorectal cancer. Diarrhea is a well-known side effect of capecitabine and 5-fluorouracil agents. We present a case with terminal ileitis as a rare adverse event of capecitabine treatment. Capecitabine-induced terminal ileitis is likely to be underreported. It should be considered more often as a cause of severe and atypical complaints of diarrhea during treatment with capecitabine or other 5-fluorouracil agents.
format Online
Article
Text
id pubmed-6243901
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-62439012018-11-27 Capecitabine-Associated Terminal Ileitis van Hellemond, Irene E.G. Thijs, Annemarie M. Creemers, Geert-Jan Case Rep Oncol Case Report Capecitabine is an oral fluoropyrimidine used as adjuvant and palliative chemotherapy in patients with colorectal cancer. Diarrhea is a well-known side effect of capecitabine and 5-fluorouracil agents. We present a case with terminal ileitis as a rare adverse event of capecitabine treatment. Capecitabine-induced terminal ileitis is likely to be underreported. It should be considered more often as a cause of severe and atypical complaints of diarrhea during treatment with capecitabine or other 5-fluorouracil agents. S. Karger AG 2018-10-22 /pmc/articles/PMC6243901/ /pubmed/30483093 http://dx.doi.org/10.1159/000492781 Text en Copyright © 2018 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
van Hellemond, Irene E.G.
Thijs, Annemarie M.
Creemers, Geert-Jan
Capecitabine-Associated Terminal Ileitis
title Capecitabine-Associated Terminal Ileitis
title_full Capecitabine-Associated Terminal Ileitis
title_fullStr Capecitabine-Associated Terminal Ileitis
title_full_unstemmed Capecitabine-Associated Terminal Ileitis
title_short Capecitabine-Associated Terminal Ileitis
title_sort capecitabine-associated terminal ileitis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6243901/
https://www.ncbi.nlm.nih.gov/pubmed/30483093
http://dx.doi.org/10.1159/000492781
work_keys_str_mv AT vanhellemondireneeg capecitabineassociatedterminalileitis
AT thijsannemariem capecitabineassociatedterminalileitis
AT creemersgeertjan capecitabineassociatedterminalileitis